Dr Reddy’s Laboratories today said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Srikakulam facility in Andhra Pradesh. The Srikakulam unit manufactures active pharmaceutical ingredients (APIs).
The EIR from the United States Food and Drug Administration (USFDA) indicates closure of the audit of the plant, Dr Reddy’s Labs said in a BSE filing.
In an earlier filing on June 2, 2018, the company had said the audit of the Srikakulam plant (SEZ) by USFDA had been completed with no observations.
Shares of Dr Reddy’s Labs were trading at Rs 2,467.05 per scrip on BSE, up 2.26 per cent from the previous close.